MedPage Today on MSN

MASLD, Risk Factors, and Mortality; Drug Monitoring in IBD; Liver Cancer, Meet AI

Meanwhile, a systematic review and meta-analysis in Lancet Gastroenterology & Hepatology examined differences in risks for ...

Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary ...

Harvard-trained doctor busts popular fatty liver myths, shares real causes and prevention tips: 'It is not caused by fats...'

In a time when misconceptions about liver health abound, Dr. Saurabh Sethi—a gastroenterologist trained at Harvard and Stanford—has taken to social media to debunk common myths surrounding fatty liver ...
The Bakersfield Californian

Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient ...

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological ...